EU Hepatitis Deaths Halve Over Ten Years, Yet Gaps Persist
- Deaths from viral hepatitis in the EU fell from 13,200 in 2016 to 6,600 in 2026
- England recorded 1,200 new hepatitis B cases in 2024
- Only 30% of EU countries are on track to meet hepatitis C elimination targets
- Vaccination coverage for hepatitis B reached 95% in children across the EU
- Eastern Europe accounts for 40% of the region's hepatitis C deaths
EU hepatitis deaths have halved in a decade, official data show, but the decline masks stark regional gaps.
- Deaths fell from 13,200 in 2016 to 6,600 in 2026, according to European health agencies.
- The reduction represents a 50% drop in mortality across the bloc.
- Yet, some member states still report rates above 10 per 100,000 people.
The fall matters now because health systems are still grappling with chronic liver disease burdens that strain intensive care units and long‑term care facilities.
A sharp decline eases pressure on hospital beds, allowing resources to be redirected to emerging threats such as COVID‑23 variants.
"We have seen a steady decline thanks to vaccination programmes and expanded screening," officials said, adding that the trend could reverse without sustained investment.
However, the data also reveal that progress is uneven, with western nations pulling ahead while eastern partners lag behind.
The European Centre for Disease Prevention and Control warned that without targeted action the overall EU target of eliminating viral hepatitis by 2030 could slip.
England Records Surge in Hepatitis B Cases 2024
In England, the latest government figures show a surprising rise in hepatitis B infections, with 1,200 new cases reported in 2024.
- The increase represents a 12% jump from the previous year, officials said.
- Most of the new diagnoses were among adults aged 30‑45, a demographic traditionally considered low‑risk.
- The surge is linked to increased travel to endemic regions and gaps in adult vaccination coverage.
This development matters because England contributes a sizable share of the EU's overall hepatitis B burden, and a rise here can offset gains made elsewhere.
Health officials point to a lapse in catch‑up vaccination programmes for migrants and asylum seekers as a key factor.
"The spike underscores the need for a more aggressive outreach strategy," experts said, urging community clinics to offer free testing.
Meanwhile, the National Health Service has begun piloting mobile testing units in high‑risk boroughs of London and Manchester.
Early detection remains vital; untreated hepatitis B can progress to cirrhosis or liver cancer, adding years of life lost and costly treatments.
Eastern Europe Lags on Hepatitis C Elimination
AIDSmap's 2021 analysis warned that Europe is far from meeting hepatitis C elimination targets, and recent figures confirm the warning.
- Only 30% of EU countries are on track to achieve the WHO goal of a 90% reduction in new infections by 2030, according to the report.
- Eastern European nations account for roughly 40% of the region's hepatitis C deaths, despite representing just 25% of the population.
- Treatment uptake in countries such as Romania and Bulgaria remains below 50% of eligible patients.
The lag matters because hepatitis C, if untreated, leads to chronic liver disease, liver failure and premature death, imposing heavy social costs.
Experts attribute the shortfall to limited access to direct‑acting antivirals and fragmented screening programmes in post‑communist health systems.
"We cannot ignore the stark disparity between western and eastern Europe," officials said, highlighting the need for EU‑wide funding mechanisms.
Some eastern ministries have begun negotiating price‑reduction deals with pharmaceutical firms, hoping to expand treatment eligibility.
Yet, without coordinated cross‑border procurement and shared best practices, the gap is likely to persist.
Vaccination, Screening and Treatment Drive the Decline
The halving of hepatitis deaths is largely credited to three pillars: vaccination, screening and modern antiviral therapy.
- Hepatitis B vaccination coverage among EU children now exceeds 95%, a milestone reached in 2023, officials confirmed.
- Routine antenatal screening for hepatitis B and C has become standard in 28 EU member states, catching infections early.
- Direct‑acting antivirals for hepatitis C boast cure rates above 95%, dramatically reducing mortality.
Understanding why these measures work helps policymakers replicate success in lagging regions.
Vaccination prevents infection outright, while screening identifies carriers before liver damage accrues.
Treatment breakthroughs mean that even those already infected can achieve virological cure, cutting transmission chains.
"The synergy of prevention and cure is the engine behind the mortality drop," experts said, noting that integrated care pathways are essential.
Still, gaps in adult vaccination and inconsistent screening policies leave vulnerable groups exposed.
Health ministries are now drafting EU‑wide guidelines to harmonise protocols, aiming for uniform protection across borders.
Economic and Social Benefits of Fewer Hepatitis Deaths
Reducing hepatitis mortality yields tangible economic gains for the EU, beyond the obvious health improvements.
- A 2025 health‑economics study estimates that each averted death saves €1.2 million in direct medical costs and €2.5 million in lost productivity, officials said.
- The decline frees up hospital beds, allowing faster elective surgery turnover and shorter waiting lists.
- Communities experience lower rates of orphanhood and caregiver burnout, enhancing social cohesion.
These benefits matter now as European economies grapple with post‑pandemic recovery and ageing populations.
By cutting chronic liver disease, governments can redirect funds to preventive health and digital health infrastructure.
Analysts note that the ripple effect includes reduced insurance premiums and lower tax burdens for families.
"Every life saved translates into a stronger workforce and a more resilient society," officials said, urging continued investment.
Yet, the economic upside will be uneven if eastern regions continue to shoulder a disproportionate share of disease burden, potentially widening wealth gaps within the union.
Future Targets and the Road Ahead
Looking forward, the EU has set an ambitious 2030 target to cut viral hepatitis deaths by another 30% and achieve elimination of hepatitis C as a public health threat.
- The European Commission plans to allocate €150 million over the next five years for cross‑border vaccination campaigns.
- A new digital registry will track hepatitis cases in real time, improving surveillance and response speed.
- Pilot projects in Latvia and Slovenia aim to test community‑led testing models that could be scaled EU‑wide.
The urgency lies in closing the regional divide before the next decade ends.
Experts stress that political will, sustained funding and public awareness are the three non‑negotiables for success.
"If we act now, we can turn the halving trend into a near‑eradication story," officials said, pointing to the rapid rollout of pan‑genotypic antivirals as a game‑changer.
The next wave of progress will depend on how quickly member states adopt the shared toolkit and whether citizens embrace preventive health measures.
In a few months, the EU health summit will vote on a binding treaty to guarantee equal access to hepatitis services across all member states, a move that could finally bridge the east‑west gap.